Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo

Cancer Research

Volumn 59, Issue 20, 1999, Pages 5059-5063

  Niu, Guilian ^a,b   Heller, Richard ^a,b   Catlett Falcone, Robyn ^a,b   Coppola, Domenico ^a,b   Jaroszeski, Mark ^b   Dalton, William ^a,b   Jove, Richard ^a,b   Yu, Hua ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STAT3 PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL STRAIN 3T3; CONTROLLED STUDY; EXPRESSION VECTOR; GENE THERAPY; GROWTH INHIBITION; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; APOPTOSIS; DNA-BINDING PROTEINS; FEMALE; GENE THERAPY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0032718891     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Darnell, J. E., Jr. STATs and gene regulation. Science (Washington DC), 277: 1630-1635, 1997.
2. Darnell, J. E., Kerr, I. M., and Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (Washington DC), 264: 1415-1421, 1994.
3. Yu, C. L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., and Jove, R. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (Washington DC), 269: 81-83, 1995.
4. Garcia, R., and Jove, R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biomed. Sci., 5: 79-85, 1998.
5. Danial, N. N., Pernis, A., and Rothman, P. B. Jak-STAT signaling induced by the v-abl oncogene. Science (Washington DC), 269: 1875-1877, 1995.
6. Cao, X., Tay, A., Guy, G. R., and Tan, Y. H. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol. Cell. Biol., 16: 1595-1603, 1996.
7. Chaturvedi, P., Sharma, S., and Reddy, E. P. Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs. Mol. Cell. Biol., 17: 3295-3304, 1997.
8. Garcia, R., Yu, C-L., Hudnall, A., Catlett, R., Nelson, K. L., Smithgall, T., Fujita, D. J., Ethier, S. P., and Jove, R. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ., 8: 1267-1276, 1997.
9. Lund, T. C., Garcia, R., Medveczky, M. M., Jove, R., and Medveczky, P. G. Activation of STAT transcription factors by herpesvirus Saimiri Tip-484 requires p561ck. J. Virol., 71: 6677-6682, 1997.
10. Besser, D., Bromberg, J. F., Darnell, J. E., Jr., and Hanafusa, H. A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol. Cell. Biol., 19: 1401-1409, 1999.
11. Turkson, J., Bowman, T., Garcia, R., Caldenhoven, E., De Groot, R. P., and Jove, R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol., 18: 2545-2552, 1998.
12. Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W., and Darnell, J. E., Jr. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol., 18: 2553-2558, 1998.
13. Gouilleux-Gruart, V., Gouilleux, F., Desaint, C., Claisse, J. F., Capiod, J. C., Delobel, J., Weber-Nordt, R., Dusanter-Fourt, I., Dreyfus, F., Groner, B., and Prin, L. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood, 87: 1692-1697, 1996.
14. Weber-Nordt, R. M., Egen, C., Wehinger, J., Ludwig, W., Gouilleux-Gruart, V., Mertelsmann, R., and Finke, J. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood, 88: 809-816, 1996.
15. Chai, S. K., Nichols, G. L., and Rothman, P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J. Immunol., 159: 4720-4728, 1997.
16. Grandis, J. R., Drenning, S. D., Chakraborty, A., Zhou, M-Y., Zeng, Q., and Pitt, A. S. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J. Clin. Investig., 102: 1385-1392, 1998.
17. Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G., Dalton, W. S., and Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10: 105-115, 1999.
18. Caldenhoven, E., van Dijk, T. B., Solari, R., Armstrong, J., Raaijmakers, J. A. M., Lammers, J. W. J., Koenderman, L., and de Groot, R. P. STAT3β, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription, J. Biol. Chem., 271: 13221-13227, 1996.
19. Heller, R., Jaroszeski, M., Atkin, A., Moradpour, D., Gilbert, R., Wands, J., and Nicolau, C. In vivo gene electroinjection and expression in rat liver. FEBS Lett., 389: 225-228, 1996.
20. Rols, M-P., Delteil, C., Golzio, M., Dumond, P., Cros, S., and Teissie, J. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat. Biotechnol., 16: 168-171, 1998.
21. Miyashita, T., Harigai, M., Hanada, M., and Reed, J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res., 54: 3131-3135, 1994.
22. Clayman, G. L., El-Naggar, A. K., Roth, J. A., Zhang, W-W., Goepfert, H., Taylor, D. L., and Liu, T-J. In vitro molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res., 55: 1-6, 1995.
23. Hamada, K., Alemany, R., Zhang, W-W., Hittelman, W. N., Lotan, R., Roth, J. A., and Mitchell, M. F. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res., 56: 3047-3054, 1996.
24. Coll, J-L., Negoescu, A., Louis, N., Sachs, L., Tenaud, C., Girardot, V., Demeinex, B., Brambilla, E., Brambilla, C., and Favrot, M. Antitumor activity of bax and p53 naked gene transfer in lung cancer in vitro and in vivo analysis. Hum. Gene Ther., 9: 2063-2074, 1998.
25. Putzer, B. M., Bramson, J. L., Addison, C. L., Hitt, M., Siegel, P. M., Muller, W. J., and Graham, F. L. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum. Gene Ther., 9: 707-718, 1998.
26. Schuler, M., Rochlitz, C., Horowitz, J. A., Schlegel, J., Perruchoud, A. P., Kommoss, F., Bolliger, C. T., Kauczor, H-U., Dalquen, P., Fritz, M. A., Swanson, S., Herrmann, R., and Huber, C. A Phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gene Ther., 9: 2075-2082, 1998.
27. Frank, D. K., Frederick, M. J., Liu, T-J., and Clayman, G. L. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. Clin. Cancer Res., 4: 2521-2528, 1998.